Influenza A virus H7N9 vaccine - Novartis Vaccines

Drug Profile

Influenza A virus H7N9 vaccine - Novartis Vaccines

Alternative Names: A/H7N9; Influenza A virus H7N9c vaccine - Novartis Vaccines; Monovalent influenza A/H7N9 virus vaccine

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator Novartis Vaccines
  • Class Influenza A vaccines; Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H7N9 subtype

Most Recent Events

  • 01 Sep 2014 Novartis Vaccines completes a phase I trial for Influenza-A virus H7N9 subtype (prevention) in USA (NCT01928472)
  • 14 Nov 2013 Interim immunogenicity data from a phase I trial in Influenza-A virus H7N9 subtype (prevention) released by Novartis Vaccines
  • 11 Sep 2013 Novartis Vaccines completes enrolment in its phase I trial for Influenza-A virus H7N9 subtype (prevention) in USA (NCT01928472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top